Erratum: Recent progress in the treatment and prevention of cancer-related lymphedema (CA Cancer Journal for Clinicians (2015) 65 (55-81) DOI: 10.3322/caac.21253);Recent progress in the treatment and prevention of cancer-related lymphedema

CA Cancer Journal for Clinicians

Volumn 65, Issue 1, 2015, Pages 55-81

  Shaitelman, Simona F ^a   Cromwell, Kate D ^a   Rasmussen, John C ^b   Stout, Nicole L ^c   Armer, Jane M ^d   Lasinski, Bonnie B ^c,e   Cormier, Janice N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e Lymphedema Therapy   (United States)

Author keywords

diagnosis; lymphedema; morbidities; treatment

Indexed keywords

SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

AXILLARY LYMPH NODE; BANDAGING TECHNIQUE; BREAST CANCER; CANCER GENETICS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVOR; CELLULITIS; CIRCUMFERENCE MEASUREMENT; COMPLETE DECONGESTIVE THERAPY; COMPRESSION THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONSERVATIVE TREATMENT; ENDOMETRIUM CANCER; GENE MUTATION; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HEREDITY; HUMAN; IMPEDANCE; INCIDENCE; KINESIOTHERAPY; LIPOSUCTION; LYMPH NODE DISSECTION; LYMPHATIC RECONSTRUCTION; LYMPHEDEMA; LYMPHOSCINTIGRAPHY; LYMPHOVENOUS ANASTOMOSIS; MEASUREMENT; MELANOMA; MINIMALLY INVASIVE PROCEDURE; MYCOSIS; NEAR INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PEROMETRY; QUALITY OF LIFE; REVIEW; SARCOMA; SENTINEL LYMPH NODE BIOPSY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN CARE; STREPTOCOCCUS INFECTION; SURGICAL TECHNIQUE; SYMPTOMATOLOGY; TISSUE TRANSFER; TISSUE TRANSPLANTATION; UROGENITAL TRACT CANCER; UTERINE CERVIX CANCER; VULVA CANCER; WATER DISPLACEMENT TECHNIQUE; WELLBEING; AXILLA; BREAST NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; INGUINAL CANAL; MALE; NECK DISSECTION; NEOPLASMS; SKIN NEOPLASMS; UROGENITAL NEOPLASMS;

AXILLA; BREAST NEOPLASMS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INGUINAL CANAL; LYMPH NODE EXCISION; LYMPHEDEMA; MALE; MELANOMA; NECK DISSECTION; NEOPLASMS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; UROGENITAL NEOPLASMS;

EID: 84920854746     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.21276     Document Type: Erratum

References (240)

1. Lawenda BD, Mondry TE, Johnstone PA,. Lymphedema: a primer on the identification and management of a chronic condition in oncologic treatment. CA Cancer J Clin. 2009; 59: 8-24.
2. Beckjord EB, Reynolds KA, van Londen G, et al. Population-level trends in posttreatment cancer survivors' concerns and associated receipt of care: results from the 2006 and 2010 LIVESTRONG surveys. J Psychosoc Oncol. 2013; 32: 125-151.
3. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993; 11: 570-579.
4. Armer JM, Henggeler MH, Brooks CW, Zagar EA, Homan S, Stewart BR,. The health deviation of post-breast cancer lymphedema: symptom assessment and impact on self-care agency. Self Care Depend Care Nurs. 2008; 16: 14-21.
5. Carter J, Raviv L, Appollo K, Baser RE, Iasonos A, Barakat RR,. A pilot study using the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) as a clinical care tool to identify lower extremity lymphedema in gynecologic cancer survivors. Gynecol Oncol. 2010; 117: 317-323.
6. Armer JM, Radina ME, Porock D, Culbertson SD,. Predicting breast cancer-related lymphedema using self-reported symptoms. Nurs Res. 2003; 52: 370-379.
7. Cella D, Nowinski CJ,. Measuring quality of life in chronic illness: the functional assessment of chronic illness therapy measurement system. Arch Phys Med Rehabil. 2002; 83 (12 suppl 2): S10-S17.
8. Pusic AL, Cemal Y, Albornoz C, et al. Quality of life among breast cancer patients with lymphedema: a systematic review of patient-reported outcome instruments and outcomes. J Cancer Surviv. 2013; 7: 83-92.
9. McWayne J, Heiney SP,. Psychologic and social sequelae of secondary lymphedema: a review. Cancer. 2005; 104: 457-466.
10. Bulley C, Coutts F, Blyth C, et al. A Morbidity Screening Tool for identifying fatigue, pain, upper limb dysfunction and lymphedema after breast cancer treatment: a validity study. Eur J Oncol Nurs. 2014; 18: 218-227.
11. Dunberger G, Lindquist H, Waldenstrom AC, Nyberg T, Steineck G, Avall-Lundqvist E,. Lower limb lymphedema in gynecological cancer survivors-effect on daily life functioning. Support Care Cancer. 2013; 21: 3063-3070.
12. Mortimer PS,. The pathophysiology of lymphedema. Cancer. 1998; 83: 2798-2802.
13. Taylor MJ, Hoerauf A, Bockarie M,. Lymphatic filariasis and onchocerciasis. Lancet. 2010; 376: 1175-1185.
14. DiSipio T, Rye S, Newman B, Hayes S,. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013; 14: 500-515.
15. Vassard D, Olsen MH, Zinckernagel L, Vibe-Petersen J, Dalton SO, Johansen C,. Psychological consequences of lymphoedema associated with breast cancer: a prospective cohort study. Eur J Cancer. 2010; 46: 3211-3218.
16. Kim SJ, Park YD,. Effects of complex decongestive physiotherapy on the oedema and the quality of life of lower unilateral lymphoedema following treatment for gynecological cancer. Eur J Cancer Care (Engl). 2008; 17: 463-468.
17. Stamataki Z, Brunton L, Lorigan P, Green AC, Newton-Bishop J, Molassiotis A,. Assessing the impact of diagnosis and the related supportive care needs in patients with cutaneous melanoma [published online ahead of print September 5, 2014]. Support Care Cancer.
18. Koshima I, Kawada S, Moriguchi T, Kajiwara Y,. Ultrastructural observations of lymphatic vessels in lymphedema in human extremities. Plast Reconstr Surg. 1996; 97: 397-405; discussion 406-407.
19. Szuba A, Rockson SG,. Lymphedema: anatomy, physiology and pathogenesis. Vasc Med. 1997; 2: 321-326.
20. Mortimer PS, Rockson SG,. New developments in clinical aspects of lymphatic disease. J Clin Invest. 2014; 124: 915-921.
21. Zuther J,. Lymphedema Management: The Comprehensive Guide for Practitioners. 2nd ed. New York: Thieme; 2009.
22. Miaskowski C, Dodd M, Paul SM, et al. Lymphatic and angiogenic candidate genes predict the development of secondary lymphedema following breast cancer surgery. PLoS One. 2013; 8: e60164.
23. Newman B, Lose F, Kedda MA, et al. Possible genetic predisposition to lymphedema after breast cancer. Lymphat Res Biol. 2012; 10: 2-13.
24. Finegold DN, Schacht V, Kimak MA, et al. HGF and MET mutations in primary and secondary lymphedema. Lymphat Res Biol. 2008; 6: 65-68.
25. Finegold DN, Baty CJ, Knickelbein KZ, et al. Connexin 47 mutations increase risk for secondary lymphedema following breast cancer treatment. Clin Cancer Res. 2012; 18: 2382-2390.
26. Leung G, Baggott C, West C, et al. Cytokine candidate genes predict the development of secondary lymphedema following breast cancer surgery. Lymphat Res Biol. 2014; 12: 10-22.
27. Lin S, Kim J, Lee MJ, et al. Prospective transcriptomic pathway analysis of human lymphatic vascular insufficiency: identification and validation of a circulating biomarker panel. PLoS One. 2012; 7: e52021.
28. DeSantis CE, Lin CC, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64: 252-271.
29. Norman SA, Localio AR, Potashnik SL, et al. Lymphedema in breast cancer survivors: incidence, degree, time course, treatment, and symptoms. J Clin Oncol. 2009; 27: 390-397.
30. Sackey H, Magnuson A, Sandelin K, et al. Arm lymphoedema after axillary surgery in women with invasive breast cancer. Br J Surg. 2014; 101: 390-397.
31. Sagen A, Kaaresen R, Sandvik L, Thune I, Risberg MA,. Upper limb physical function and adverse effects after breast cancer surgery: a prospective 2.5-year follow-up study and preoperative measures. Arch Phys Med Rehabil. 2014; 95: 875-881.
32. Velloso FS, Barra AA, Dias RC,. Functional performance of upper limb and quality of life after sentinel lymph node biopsy of breast cancer. Rev Bras Fisioter. 2011; 15: 146-153.
33. Goldberg JI, Wiechmann LI, Riedel ER, Morrow M, Van Zee KJ,. Morbidity of sentinel node biopsy in breast cancer: the relationship between the number of excised lymph nodes and lymphedema. Ann Surg Oncol. 2010; 17: 3278-3286.
34. Lucci A, McCall LM, Beitsch PD, et al. American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007; 25: 3657-3663.
35. Langer I, Guller U, Berclaz G, et al. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg. 2007; 245: 452-461.
36. Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98: 599-609.
37. Francis WP, Abghari P, Du W, Rymal C, Suna M, Kosir MA,. Improving surgical outcomes: standardizing the reporting of incidence and severity of acute lymphedema after sentinel lymph node biopsy and axillary lymph node dissection. Am J Surg. 2006; 192: 636-639.
38. Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006; 13: 491-500.
39. Leidenius M, Krogerus L, Tukiainen E, von Smitten K,. Accuracy of axillary staging using sentinel node biopsy or diagnostic axillary lymph node dissection-a case-control study. APMIS. 2004; 112: 264-270.
40. Ronka R, Smitten K, Sintonen H, et al. The impact of sentinel node biopsy and axillary staging strategy on hospital costs. Ann Oncol. 2004; 15: 88-94.
41. Langer S, Guenther JM, Haigh PI, Difronzo LA,. Lymphatic mapping improves staging and reduces morbidity in women undergoing total mastectomy for breast carcinoma. Am Surg. 2004; 70: 881-885.
42. Blanchard E, Herman L, Larson L, et al. Understanding the role of sentinel lymph node biopsy in breast cancer and melanoma. JAAPA. 2003; 16: 49-50, 54.
43. Haid A, Koberle-Wuhrer R, Knauer M, et al. Morbidity of breast cancer patients following complete axillary dissection or sentinel node biopsy only: a comparative evaluation. Breast Cancer Res Treat. 2002; 73: 31-36.
44. Swenson KK, Nissen MJ, Ceronsky C, Swenson L, Lee MW, Tuttle TM,. Comparison of side effects between sentinel lymph node and axillary lymph node dissection for breast cancer. Ann Surg Oncol. 2002; 9: 745-753.
45. Sener SF, Winchester DJ, Martz CH, et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer. 2001; 92: 748-752.
46. Schrenk P, Rieger R, Shamiyeh A, Wayand W,. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000; 88: 608-614.
47. Rutgers EJ DM, Evelien Straver M, Meijnen P, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer patients: final analysis of the EORTC AMAROs trial (10981/22023) [abstract]. J Clin Oncol. 2013; 31 (suppl). Abstract LBA 1001.
48. Ashikaga T, Krag DN, Land SR, et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010; 102: 111-118.
49. Teshome M BK, McCall LM, Cormier JN, Giuliano AE, Hunt KK,. Long-term incidence of lymphedema after sentinel lymph node dissection for early stage breast cancer: ACOSOG Z0010. Presented at: Society of Surgical Oncology 67th Annual Cancer Symposium; March 12-15, 2014; Phoenix, AZ.
50. Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM,. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010; 116: 5138-5149.
51. Hyngstrom JR, Chiang YJ, Cromwell KD, et al. Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res. 2013; 23: 290-297.
52. Murawa D, Polom K, Murawa P,. One-year postoperative morbidity associated with near-infrared-guided indocyanine green (ICG) or ICG in conjugation with human serum albumin (ICG:HSA) sentinel lymph node biopsy. Surg Innov. 2013; 21: 240-243.
53. Palmer PE, 3rd, Warneke CL, Hayes-Jordan AA, et al. Complications in the surgical treatment of pediatric melanoma. J Pediatr Surg. 2013; 48: 1249-1253.
54. de Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ,. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol. 2006; 32: 785-789.
55. de Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ,. Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. Eur J Surg Oncol. 2005; 31: 778-783.
56. Roaten JB, Pearlman N, Gonzalez R, Gonzalez R, McCarter MD,. Identifying risk factors for complications following sentinel lymph node biopsy for melanoma. Arch Surg. 2005; 140: 85-89.
57. Starritt EC, Joseph D, McKinnon JG, Lo SK, de Wilt JH, Thompson JF,. Lymphedema after complete axillary node dissection for melanoma: assessment using a new, objective definition. Ann Surg. 2004; 240: 866-874.
58. Serpell JW, Carne PW, Bailey M,. Radical lymph node dissection for melanoma. ANZ J Surg. 2003; 73: 294-299.
59. Burmeister BH, Smithers BM, Davis S, et al. Radiation therapy following nodal surgery for melanoma: an analysis of late toxicity. ANZ J Surg. 2002; 72: 344-348.
60. Lawton G, Rasque H, Ariyan S,. Preservation of muscle fascia to decrease lymphedema after complete axillary and ilioinguinofemoral lymphadenectomy for melanoma. J Am Coll Surg. 2002; 195: 339-351.
61. Bowsher WG, Taylor BA, Hughes LE,. Morbidity, mortality and local recurrence following regional node dissection for melanoma. Br J Surg. 1986; 73: 906-908.
62. Urist MM, Maddox WA, Kennedy JE, Balch CM,. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer. 1983; 51: 2152-2156.
63. Brouns E, Donceel P, Stas M,. Quality of life and disability after ilio-inguinal lymphadenectomy. Acta Chir Belg. 2008; 108: 685-690.
64. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. Ann Surg Oncol. 2003; 10: 676-680.
65. Baas PC, Schraffordt Koops H, Hoekstra HJ, van Bruggen JJ, van der Weele LT, Oldhoff J,. Groin dissection in the treatment of lower-extremity melanoma. Short-term and long-term morbidity. Arch Surg. 1992; 127: 281-286.
66. Karakousis CP, Heiser MA, Moore RH,. Lymphedema after groin dissection. Am J Surg. 1983; 145: 205-208.
67. James JH,. Lymphoedema following ilio-inguinal lymph node dissection. Scand J Plast Reconstr Surg. 1982; 16: 167-171.
68. Holmes EC, Moseley HS, Morton DL, Clark W, Robinson D, Urist MM,. A rational approach to the surgical management of melanoma. Ann Surg. 1977; 186: 481-490.
69. Papachristou D, Fortner JG,. Comparison of lymphedema following incontinuity and discontinuity groin dissection. Ann Surg. 1977; 185: 13-16.
70. Carlson JW, Kauderer J, Walker JL, et al. Gynecologic Oncology Group. A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study. Gynecol Oncol. 2008; 110: 76-82.
71. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol. 2008; 26: 884-889.
72. Moore RG, Robison K, Brown AK, et al. Isolated sentinel lymph node dissection with conservative management in patients with squamous cell carcinoma of the vulva: a prospective trial. Gynecol Oncol. 2008; 109: 65-70.
73. Zhang X, Sheng X, Niu J, et al. Sparing of saphenous vein during inguinal lymphadenectomy for vulval malignancies. Gynecol Oncol. 2007; 105: 722-726.
74. Bellati F, Napoletano C, Tarquini E, et al. Cancer testis antigen expression in primary and recurrent vulvar cancer: association with prognostic factors. Eur J Cancer. 2007; 43: 2621-2627.
75. Judson PL, Jonson AL, Paley PJ, et al. A prospective, randomized study analyzing sartorius transposition following inguinal-femoral lymphadenectomy. Gynecol Oncol. 2004; 95: 226-230.
76. Gaarenstroom KN, Kenter GG, Trimbos JB, et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer. 2003; 13: 522-527.
77. de Hullu JA, Ansink AC, Tymstra T, van der Zee AG,. What doctors and patients think about false-negative sentinel lymph nodes in vulvar cancer. J Psychosom Obstet Gynaecol. 2001; 22: 199-203.
78. Tanaka T, Ohki N, Kojima A, et al. Radiotherapy negates the effect of retroperitoneal nonclosure for prevention of lymphedema of the legs following pelvic lymphadenectomy for gynecological malignancies: an analysis from a questionnaire survey. Int J Gynecol Cancer. 2007; 17: 460-464.
79. Fujiwara K, Kigawa J, Hasegawa K, et al. Effect of simple omentoplasty and omentopexy in the prevention of complications after pelvic lymphadenectomy. Int J Gynecol Cancer. 2003; 13: 61-66.
80. Bergmark K, Avall-Lundqvist E, Dickman PW, Henningsohn L, Steineck G,. Patient-rating of distressful symptoms after treatment for early cervical cancer. Acta Obstet Gynecol Scand. 2002; 81: 443-450.
81. Uno T, Ito H, Itami J, et al. Postoperative radiation therapy for stage IB-IIB carcinoma of the cervix with poor prognostic factors. Anticancer Res. 2000; 20: 2235-2239.
82. Kridelka FJ, Berg DO, Neuman M, et al. Adjuvant small field pelvic radiation for patients with high risk, stage IB lymph node negative cervix carcinoma after radical hysterectomy and pelvic lymph node dissection. A pilot study. Cancer. 1999; 86: 2059-2065.
83. Logmans A, Kruyt RH, de Bruin HG, Cox PH, Pillay M, Trimbos JB,. Lymphedema and lymphocysts following lymphadenectomy may be prevented by omentoplasty: a pilot study. Gynecol Oncol. 1999; 75: 323-327.
84. Snijders-Keilholz A, Hellebrekers BW, Zwinderman AH, van de Vijver MJ, Trimbos JB,. Adjuvant radiotherapy following radical hysterectomy for patients with early-stage cervical carcinoma (1984-1996). Radiother Oncol. 1999; 51: 161-167.
85. Yeh SA, Wan Leung S, Wang CJ, Chen HC,. Postoperative radiotherapy in early stage carcinoma of the uterine cervix: treatment results and prognostic factors. Gynecol Oncol. 1999; 72: 10-15.
86. Chatani M, Nose T, Masaki N, Inoue T,. Adjuvant radiotherapy after radical hysterectomy of the cervical cancer. Prognostic factors and complications. Strahlenther Onkol. 1998; 174: 504-509.
87. Werngren-Elgstrom M, Lidman D,. Lymphoedema of the lower extremities after surgery and radiotherapy for cancer of the cervix. Scand J Plast Reconstr Surg Hand Surg. 1994; 28: 289-293.
88. Fiorica JV, Roberts WS, Greenberg H, Hoffman MS, LaPolla JP, Cavanagh D,. Morbidity and survival patterns in patients after radical hysterectomy and postoperative adjuvant pelvic radiotherapy. Gynecol Oncol. 1990; 36: 343-347.
89. Bilek K, Ebeling K, Leitsmann H, Seidel G,. Radical pelvic surgery versus radical surgery plus radiotherapy for stage Ib carcinoma of the cervix uteri. Preliminary results of a prospective randomized clinical study. Arch Geschwulstforsch. 1982; 52: 223-229.
90. Martimbeau PW, Kjorstad KE, Kolstad P,. Stage IB carcinoma of the cervix, the Norwegian Radium Hospital, 1968-1970: results of treatment and major complications. I. Lymphedema. Am J Obstet Gynecol. 1978; 131: 389-394.
91. Orr JW Jr, Holloway RW, Orr PF, Holimon JL,. Surgical staging of uterine cancer: an analysis of perioperative morbidity. Gynecol Oncol. 1991; 42: 209-216.
92. Robison K, Roque D, McCourt C, et al. Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone. Gynecol Oncol. 2014; 133: 416-420.
93. Achouri A, Huchon C, Bats AS, Bensaid C, Nos C, Lecuru F,. Complications of lymphadenectomy for gynecologic cancer. Eur J Surg Oncol. 2013; 39: 81-86.
94. Novackova M, Halaska MJ, Robova H, et al. A prospective study in detection of lower-limb lymphedema and evaluation of quality of life after vulvar cancer surgery. Int J Gynecol Cancer. 2012; 22: 1081-1088.
95. Niikura H, Okamoto S, Otsuki T, et al. Prospective study of sentinel lymph node biopsy without further pelvic lymphadenectomy in patients with sentinel lymph node-negative cervical cancer. Int J Gynecol Cancer. 2012; 22: 1244-1250.
96. Wolff HA, Overbeck T, Roedel RM, et al. Toxicity of daily low dose cisplatin in radiochemotherapy for locally advanced head and neck cancer. J Cancer Res Clin Oncol. 2009; 135: 961-967.
97. Deng J, Ridner SH, Dietrich MS, et al. Prevalence of secondary lymphedema in patients with head and neck cancer. J Pain Symptom Manage. 2012; 43: 244-252.
98. Jacobellis U,. Modified radical inguinal lymphadenectomy for carcinoma of the penis: technique and results. J Urol. 2003; 169: 1349-1352.
99. Ravi R,. Morbidity following groin dissection for penile carcinoma. Br J Urol. 1993; 72: 941-945.
100. Henningsohn L, Wijkstrom H, Dickman PW, Bergmark K, Steineck G,. Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol. 2002; 62: 215-225.
101. Clark PB,. Radical cystectomy for carcinoma of the bladder. Br J Urol. 1978; 50: 492-495.
102. Kavoussi LR, Sosa E, Chandhoke P, et al. Complications of laparoscopic pelvic lymph node dissection. J Urol. 1993; 149: 322-325.
103. Greskovich FJ, Zagars GK, Sherman NE, Johnson DE,. Complications following external beam radiation therapy for prostate cancer: an analysis of patients treated with and without staging pelvic lymphadenectomy. J Urol. 1991; 146: 798-802.
104. Rainwater LM, Zincke H,. Radical prostatectomy after radiation therapy for cancer of the prostate: feasibility and prognosis. J Urol. 1988; 140: 1455-1459.
105. Lieskovsky G, Skinner DG, Weisenburger T,. Pelvic lymphadenectomy in the management of carcinoma of the prostate. J Urol. 1980; 124: 635-638.
106. Robinson MH, Spruce L, Eeles R, et al. Limb function following conservation treatment of adult soft tissue sarcoma. Eur J Cancer. 1991; 27: 1567-1574.
107. Whelan TJ,. NCIC-CTG MA. 20: an intergroup trial of regional nodal irradiation in early breast cancer [abstract]. J Clin Oncol. 2011; 29 (suppl). Abstract LBA 1003.
108. Armer JM, Stewart BR,. A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population. Lymphat Res Biol. 2005; 3: 208-217.
109. Stout Gergich NL, Pfalzer LA, McGarvey C, Springer B, Gerber LH, Soballe P,. Preoperative assessment enables the early diagnosis and successful treatment of lymphedema. Cancer. 2008; 112: 2809-2819.
110. Petrek JA, Pressman PI, Smith RA,. Lymphedema: current issues in research and management. CA Cancer J Clin. 2000; 50: 292-307; quiz 308-311.
111. Paskett ED, Dean JA, Oliveri JM, Harrop JP,. Cancer-related lymphedema risk factors, diagnosis, treatment, and impact: a review. J Clin Oncol. 2012; 30: 3726-3733.
112. Gerber LH,. A review of measures of lymphedema. Cancer. 1998; 83: 2803-2804.
113. Swedborg I,. Voluminometric estimation of the degree of lymphedema and its therapy by pneumatic compression. Scand J Rehabil Med. 1977; 9: 131-135.
114. Stout NL, Pfalzer LA, Levy E, et al. Segmental limb volume change as a predictor of the onset of lymphedema in women with early breast cancer. PM R. 2011; 3: 1098-1105.
115. Tierney S, Aslam M, Rennie K, Grace P,. Infrared optoelectronic volumetry, the ideal way to measure limb volume. Eur J Vasc Endovasc Surg. 1996; 12: 412-417.
116. Ward LC, Dylke E, Czerniec S, Isenring E, Kilbreath SL,. Confirmation of the reference impedance ratios used for assessment of breast cancer-related lymphedema by bioelectrical impedance spectroscopy. Lymphat Res Biol. 2011; 9: 47-51.
117. Cornish BH, Chapman M, Hirst C, et al. Early diagnosis of lymphedema using multiple frequency bioimpedance. Lymphology. 2001; 34: 2-11.
118. Ridner SH, Dietrich MS, Deng J, Bonner CM, Kidd N,. Bioelectrical impedance for detecting upper limb lymphedema in nonlaboratory settings. Lymphat Res Biol. 2009; 7: 11-15.
119. Adriaenssens N, Buyl R, Lievens P, Fontaine C, Lamote J,. Comparative study between mobile infrared optoelectronic volumetry with a perometer and two commonly used methods for the evaluation of arm volume in patients with breast cancer related lymphedema of the arm. Lymphology. 2013; 46: 132-143.
120. Deltombe T, Jamart J, Recloux S, et al. Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema. Lymphology. 2007; 40: 26-34.
121. Armer J, Fu MR,. Age differences in post-breast cancer lymphedema signs and symptoms. Cancer Nurs. 2005; 28: 200-207; quiz 208-209.
122. Gartner R, Jensen MB, Kronborg L, Ewertz M, Kehlet H, Kroman N,. Self-reported arm-lymphedema and functional impairment after breast cancer treatment-a nationwide study of prevalence and associated factors. Breast. 2010; 19: 506-515.
123. Foldi M,. Textbook of Lymphology For Physicians and Lymphedema Therapists. Maryland Heights, MO: Mosby Inc; 2012.
124. International Society of Lymphology. The diagnosis and treatment of peripheral lymphedema: 2013 Consensus Document of the International Society of Lymphology. Lymphology. 2013; 46: 1-11.
125. Smith BG, Lewin JS,. Lymphedema management in head and neck cancer. Curr Opin Otolaryngol Head Neck Surg. 2010; 18: 153-158.
126. Bulley C, Gaal S, Coutts F, et al. Comparison of breast cancer-related lymphedema (upper limb swelling) prevalence estimated using objective and subjective criteria and relationship with quality of life. Biomed Res Int. 2013; 2013: 807569.
127. Webster K, Cella D, Yost K,. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation. Health Qual Life Outcomes. 2003; 1: 79.
128. Hayes S, Cornish B, Newman B,. Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat. 2005; 89: 221-226.
129. Armer JM, Stewart BR, Shook RP,. 30-month post-breast cancer treatment lymphoedema. J Lymphoedema. 2009; 4: 14-18.
130. Armer JM, Whitman M,. The problem of lymphedema following breast cancer treatment: prevalence, symptoms, and self-management. Lymphology. 2002; 35 (suppl): 153-159.
131. Cemal Y, Jewell S, Albornoz CR, Pusic A, Mehrara BJ,. Systematic review of quality of life and patient reported outcomes in patients with oncologic related lower extremity lymphedema. Lymphat Res Biol. 2013; 11: 14-19.
132. Ridner SH,. The psycho-social impact of lymphedema. Lymphat Res Biol. 2009; 7: 109-112.
133. Sevick-Muraca EM, Kwon S, Rasmussen JC,. Emerging lymphatic imaging technologies for mouse and man. J Clin Invest. 2014; 124: 905-914.
134. Rasmussen JC, Tan IC, Marshall MV, et al. Human lymphatic architecture and dynamic transport imaged using near-infrared fluorescence. Transl Oncol. 2010; 3: 362-372.
135. Rasmussen JC, Tan IC, Marshall MV, Fife CE, Sevick-Muraca EM,. Lymphatic imaging in humans with near-infrared fluorescence. Curr Opin Biotechnol. 2009; 20: 74-82.
136. Kitai T, Inomoto T, Miwa M, Shikayama T,. Fluorescence navigation with indocyanine green for detecting sentinel lymph nodes in breast cancer. Breast Cancer. 2005; 12: 211-215.
137. Sevick-Muraca EM, Sharma R, Rasmussen JC, et al. Imaging of lymph flow in breast cancer patients after microdose administration of a near-infrared fluorophore: feasibility study. Radiology. 2008; 246: 734-741.
138. Miyashiro I, Miyoshi N, Hiratsuka M, et al. Detection of sentinel node in gastric cancer surgery by indocyanine green fluorescence imaging: comparison with infrared imaging. Ann Surg Oncol. 2008; 15: 1640-1643.
139. Fujiwara M, Mizukami T, Suzuki A, Fukamizu H,. Sentinel lymph node detection in skin cancer patients using real-time fluorescence navigation with indocyanine green: preliminary experience. J Plast Reconstr Aesthet Surg. 2009; 62: e373-e378.
140. Furukawa H, Osawa M, Saito A, et al. Microsurgical lymphaticovenous implantation targeting dermal lymphatic backflow using indocyanine green fluorescence lymphography in the treatment of postmastectomy lymphedema. Plast Reconstr Surg. 2011; 127: 1804-1811.
141. Ogata F, Narushima M, Mihara M, Azuma R, Morimoto Y, Koshima I,. Intraoperative lymphography using indocyanine green dye for near-infrared fluorescence labeling in lymphedema. Ann Plast Surg. 2007; 59: 180-184.
142. Maus EA, Tan IC, Rasmussen JC, et al. Near-infrared fluorescence imaging of lymphatics in head and neck lymphedema. Head Neck. 2012; 34: 448-453.
143. Rasmussen JC, Kwon S, Sevick-Muraca EM, Cormier JN,. The role of lymphatics in cancer as assessed by near-infrared fluorescence imaging. Ann Biomed Eng. 2012; 40: 408-421.
144. Unno N, Inuzuka K, Suzuki M, et al. Preliminary experience with a novel fluorescence lymphography using indocyanine green in patients with secondary lymphedema. J Vasc Surg. 2007; 45: 1016-1021.
145. Tan IC, Maus EA, Rasmussen JC, et al. Assessment of lymphatic contractile function after manual lymphatic drainage using near-infrared fluorescence imaging. Arch Phys Med Rehabil. 2011; 92: 756-764.e1.
146. Adams KE, Rasmussen JC, Darne C, et al. Direct evidence of lymphatic function improvement after advanced pneumatic compression device treatment of lymphedema. Biomed Opt Express. 2010; 1: 114-125.
147. Baulieu F, Bourgeois P, Maruani A, et al. Contributions of SPECT/CT imaging to the lymphoscintigraphic investigations of the lower limb lymphedema. Lymphology. 2013; 46: 106-119.
148. Pecking AP, Wartski M, Cluzan RV, Bellet D, Alberini JL,. SPECT-CT fusion imaging radionuclide lymphoscintigraphy: potential for limb lymphedema assessment and sentinel node detection in breast cancer. Cancer Treat Res. 2007; 135: 79-84.
149. Cheville AL, Brinkmann DH, Ward SB, et al. The addition of SPECT/CT lymphoscintigraphy to breast cancer radiation planning spares lymph nodes critical for arm drainage. Int J Radiat Oncol Biol Phys. 2013; 85: 971-977.
150. Lu Q, Delproposto Z, Hu A, et al. MR lymphography of lymphatic vessels in lower extremity with gynecologic oncology-related lymphedema. PLoS One. 2012; 7: e50319.
151. US Department of Health and Human Services, National Institutes of Health, National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03. evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf. Accessed July 17, 2014.
152. Cormier JN, Xing Y, Zaniletti I, Askew RL, Stewart BR, Armer JM,. Minimal limb volume change has a significant impact on breast cancer survivors. Lymphology. 2009; 42: 161-175.
153. Spillane AJ, Saw RP, Tucker M, Byth K, Thompson JF,. Defining lower limb lymphedema after inguinal or ilio-inguinal dissection in patients with melanoma using classification and regression tree analysis. Ann Surg. 2008; 248: 286-293.
154. Deng J, Ridner SH, Dietrich MS, Wells N, Murphy BA,. Assessment of external lymphedema in patients with head and neck cancer: a comparison of four scales. Oncol Nurs Forum. 2013; 40: 501-506.
155. Javid SH, Anderson BO,. Mounting evidence against complex decongestive therapy as a first-line treatment for early lymphedema. J Clin Oncol. 2013; 31: 3737-3738.
156. Lasinski BB, McKillip Thrift K, Squire D, et al. A systematic review of the evidence for complete decongestive therapy in the treatment of lymphedema from 2004 to 2011. PM R. 2012; 4: 580-601.
157. Dayes IS, Whelan TJ, Julian JA, et al. Randomized trial of decongestive lymphatic therapy for the treatment of lymphedema in women with breast cancer. J Clin Oncol. 2013; 31: 3758-3763.
158. O'Toole J, Jammallo LS, Skolny MN, et al. Lymphedema following treatment for breast cancer: a new approach to an old problem. Crit Rev Oncol Hematol. 2013; 88: 437-446.
159. Huang TW, Tseng SH, Lin CC, et al. Effects of manual lymphatic drainage on breast cancer-related lymphedema: a systematic review and meta-analysis of randomized controlled trials. World J Surg Oncol. 2013; 11: 15.
160. Kasseroller RG,. The Vodder School: the Vodder method. Cancer. 1998; 83 (suppl 12): 2840-2842.
161. Karki A, Anttila H, Tasmuth T, Rautakorpi UM,. Lymphoedema therapy in breast cancer patients: a systematic review on effectiveness and a survey of current practices and costs in Finland. Acta Oncol. 2009; 48: 850-859.
162. Kwan ML, Cohn JC, Armer JM, Stewart BR, Cormier JN,. Exercise in patients with lymphedema: a systematic review of the contemporary literature. J Cancer Surviv. 2011; 5: 320-336.
163. Hayes SC, Reul-Hirche H, Turner J,. Exercise and secondary lymphedema: safety, potential benefits, and research issues. Med Sci Sports Exerc. 2009; 41: 483-489.
164. Alfano CM, Molfino A, Muscaritoli M,. Interventions to promote energy balance and cancer survivorship: priorities for research and care. Cancer. 2013; 119 (suppl 11): 2143-2150.
165. Denlinger CS, Ligibel JA, Are M, et al. Survivorship: healthy lifestyles, version 2.2014. J Natl Compr Canc Netw. 2014; 12: 1222-1237.
166. Johansson K, Hayes S, Speck RM, Schmitz KH,. Water-based exercise for patients with chronic arm lymphedema: a randomized controlled pilot trial. Am J Phys Med Rehabil. 2013; 92: 312-319.
167. Brown JC, John GM, Segal S, Chu CS, Schmitz KH,. Physical activity and lower limb lymphedema among uterine cancer survivors. Med Sci Sports Exerc. 2013; 45: 2091-2097.
168. Cormier JN, Rourke L, Crosby M, Chang D, Armer J,. The surgical treatment of lymphedema: a systematic review of the contemporary literature (2004-2010). Ann Surg Oncol. 2012; 19: 642-651.
169. Dumanian GA, Futrell JW,. The Charles procedure: misquoted and misunderstood since 1950. Plast Reconstr Surg. 1996; 98: 1258-1263.
170. Karri V, Yang MC, Lee IJ, et al. Optimizing outcome of Charles procedure for chronic lower extremity lymphoedema. Ann Plast Surg. 2011; 66: 393-402.
171. Sapountzis S, Ciudad P, Lim SY, et al. Modified Charles procedure and lymph node flap transfer for advanced lower extremity lymphedema. Microsurgery. 2014; 34: 439-447.
172. Kim DI, Huh SH, Hwang JH, Joh JH,. Excisional surgery for chronic advanced lymphedema. Surg Today. 2004; 34: 134-137.
173. Modolin M, Mitre AI, da Silva JC, et al. Surgical treatment of lymphedema of the penis and scrotum. Clinics (Sao Paulo). 2006; 61: 289-294.
174. Lee BB, Kim YW, Kim DI, Hwang JH, Laredo J, Neville R,. Supplemental surgical treatment to end stage (stage IV-V) of chronic lymphedema. Int Angiol. 2008; 27: 389-395.
175. Salgado CJ,. Radical reduction of upper extremity lymphedema with preservation of perforators. Ann Plast Surg. 2009; 63: 302-306.
176. van der Walt JC, Perks TJ, Zeeman BJ, Bruce-Chwatt AJ, Graewe FR,. Modified Charles procedure using negative pressure dressings for primary lymphedema: a functional assessment. Ann Plast Surg. 2009; 62: 669-675.
177. Liu Q, Zhou X, Wei Q,. Treatment of upper limb lymphedema after radical mastectomy with liposuction technique and pressure therapy [in Chinese]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2005; 19: 344-345.
178. Brorson H, Ohlin K, Olsson G, Langstrom G, Wiklund I, Svensson H,. Quality of life following liposuction and conservative treatment of arm lymphedema. Lymphology. 2006; 39: 8-25.
179. Granzow JW, Soderberg JM, Kaji AH, Dauphine C,. An effective system of surgical treatment of lymphedema. Ann Surg Oncol. 2014; 21: 1189-1194.
180. Qi F, Gu J, Shi Y, Yang Y,. Treatment of upper limb lymphedema with combination of liposuction, myocutaneous flap transfer, and lymph-fascia grafting: a preliminary study. Microsurgery. 2009; 29: 29-34.
181. Damstra RJ, Voesten HG, Klinkert P, Brorson H,. Circumferential suction-assisted lipectomy for lymphoedema after surgery for breast cancer. Br J Surg. 2009; 96: 859-864.
182. Schaverien MV, Munro KJ, Baker PA, Munnoch DA,. Liposuction for chronic lymphoedema of the upper limb: 5 years of experience. J Plast Reconstr Aesthet Surg. 2012; 65: 935-942.
183. Koshima I, Nanba Y, Tsutsui T, Takahashi Y, Itoh S, Fujitsu M,. Minimal invasive lymphaticovenular anastomosis under local anesthesia for leg lymphedema: is it effective for stage III and IV? Ann Plast Surg. 2004; 53: 261-266.
184. Matsubara S, Sakuda H, Nakaema M, Kuniyoshi Y,. Long-term results of microscopic lymphatic vessel-isolated vein anastomosis for secondary lymphedema of the lower extremities. Surg Today. 2006; 36: 859-864.
185. Damstra RJ, Voesten HG, van Schelven WD, van der Lei B,. Lymphatic venous anastomosis (LVA) for treatment of secondary arm lymphedema. A prospective study of 11 LVA procedures in 10 patients with breast cancer related lymphedema and a critical review of the literature. Breast Cancer Res Treat. 2009; 113: 199-206.
186. Demirtas Y, Ozturk N, Yapici O, Topalan M,. Supermicrosurgical lymphaticovenular anastomosis and lymphaticovenous implantation for treatment of unilateral lower extremity lymphedema. Microsurgery. 2009; 29: 609-618.
187. Campisi C, Bellini C, Accogli S, Bonioli E, Boccardo F,. Microsurgery for lymphedema: clinical research and long-term results. Microsurgery. 2010; 30: 256-260.
188. Chang DW,. Lymphaticovenular bypass for lymphedema management in breast cancer patients: a prospective study. Plast Reconstr Surg. 2010; 126: 752-758.
189. Maegawa J, Mikami T, Yamamoto Y, Satake T, Kobayashi S,. Types of lymphoscintigraphy and indications for lymphaticovenous anastomosis. Microsurgery. 2010; 30: 437-442.
190. Mihara M, Hayashi Y, Murai N, et al. Regional diagnosis of lymphoedema and selection of sites for lymphaticovenular anastomosis using elastography. Clin Radiol. 2010; 66: 715-719.
191. Narushima M, Mihara M, Yamamoto Y, Iida T, Koshima I, Mundinger GS,. The intravascular stenting method for treatment of extremity lymphedema with multiconfiguration lymphaticovenous anastomoses. Plast Reconstr Surg. 2010; 125: 935-943.
192. Yamamoto T, Narushima M, Kikuchi K, et al. Lambda-shaped anastomosis with intravascular stenting method for safe and effective lymphaticovenular anastomosis. Plast Reconstr Surg. 2011; 127: 1987-1992.
193. Auba C, Marre D, Rodriguez-Losada G, Hontanilla B,. Lymphaticovenular anastomoses for lymphedema treatment: 18 months postoperative outcomes. Microsurgery. 2012; 32: 261-268.
194. Mihara M, Hara H, Kikuchi K, et al. Scarless lymphatic venous anastomosis for latent and early-stage lymphoedema using indocyanine green lymphography and non-invasive instruments for visualising subcutaneous vein. J Plast Reconstr Aesthet Surg. 2012; 65: 1551-1558.
195. Ayestaray B, Bekara F, Andreoletti JB,. Pi-shaped lymphaticovenular anastomosis for head and neck lymphoedema: a preliminary study. J Plast Reconstr Aesthet Surg. 2013; 66: 201-206.
196. Boccardo F, De Cian F, Campisi CC, et al. Surgical prevention and treatment of lymphedema after lymph node dissection in patients with cutaneous melanoma. Lymphology. 2013; 46: 20-26.
197. Chang DW, Suami H, Skoracki R,. A prospective analysis of 100 consecutive lymphovenous bypass cases for treatment of extremity lymphedema. Plast Reconstr Surg. 2013; 132: 1305-1314.
198. Yamamoto T, Yamamoto N, Numahata T, et al. Navigation lymphatic supermicrosurgery for the treatment of cancer-related peripheral lymphedema. Vasc Endovascular Surg. 2014; 48: 139-143.
199. Raju A, Chang DW,. Vascularized lymph node transfer for treatment of lymphedema: a comprehensive literature review [published online ahead of print June 19, 2014]. Ann Surg.
200. Weiss M, Baumeister RG, Hahn K,. Post-therapeutic lymphedema: scintigraphy before and after autologous lymph vessel transplantation: 8 years of long-term follow-up. Clin Nucl Med. 2002; 27: 788-792.
201. Wongtrungkapun R,. Microsurgical lymphonodovenous implantation for chronic lymphedema. J Med Assoc Thai. 2004; 87: 877-882.
202. Becker C, Assouad J, Riquet M, Hidden G,. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg. 2006; 243: 313-315.
203. Belcaro G, Errichi BM, Cesarone MR, et al. Lymphatic tissue transplant in lymphedema-a minimally invasive, outpatient, surgical method: a 10-year follow-up pilot study. Angiology. 2008; 59: 77-83.
204. Hou C, Wu X, Jin X,. Autologous bone marrow stromal cells transplantation for the treatment of secondary arm lymphedema: a prospective controlled study in patients with breast cancer related lymphedema. Jpn J Clin Oncol. 2008; 38: 670-674.
205. Lin CH, Ali R, Chen SC, et al. Vascularized groin lymph node transfer using the wrist as a recipient site for management of postmastectomy upper extremity lymphedema. Plast Reconstr Surg. 2009; 123: 1265-1275.
206. Gharb BB, Rampazzo A, Spanio di Spilimbergo S, Xu ES, Chung KP, Chen HC,. Vascularized lymph node transfer based on the hilar perforators improves the outcome in upper limb lymphedema. Ann Plast Surg. 2011; 67: 589-593.
207. Saaristo AM, Niemi TS, Viitanen TP, Tervala TV, Hartiala P, Suominen EA,. Microvascular breast reconstruction and lymph node transfer for postmastectomy lymphedema patients. Ann Surg. 2012; 255: 468-473.
208. Cheng MH, Chen SC, Henry SL, Tan BK, Lin MC, Huang JJ,. Vascularized groin lymph node flap transfer for postmastectomy upper limb lymphedema: flap anatomy, recipient sites, and outcomes. Plast Reconstr Surg. 2013; 131: 1286-1298.
209. Dancey A, Nassimizadeh A, Nassimizadeh M, Warner RM, Waters R,. A chimeric vascularised groin lymph node flap and DIEP flap for the management of lymphoedema secondary to breast cancer. J Plast Reconstr Aesthet Surg. 2013; 66: 735-737.
210. Vignes S, Blanchard M, Yannoutsos A, Arrault M,. Complications of autologous lymph-node transplantation for limb lymphoedema. Eur J Vasc Endovasc Surg. 2013; 45: 516-520.
211. Morton DL, Thompson JF, Cochran AJ, et al. MSLT Group. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370: 599-609.
212. National Comprehensive Cancer Network. NCCN Guidelines for Physicians: Melanoma. nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed May 21, 2014.
213. World Health Organization. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. globocan.iarc.fr/Pages/fact-sheets-population.aspx. Accessed April 22, 2014.
214. Noguchi M,. Axillary reverse mapping for preventing lymphedema in axillary lymph node dissection and/or sentinel lymph node biopsy. Breast Cancer. 2010; 17: 155-157.
215. Klimberg VS,. A new concept toward the prevention of lymphedema: axillary reverse mapping. J Surg Oncol. 2008; 97: 563-564.
216. Toi M, Winer EP, Inamoto T, et al. Identifying gaps in the locoregional management of early breast cancer: highlights from the Kyoto Consensus Conference. Ann Surg Oncol. 2011; 18: 2885-2892.
217. Boneti C, Korourian S, Diaz Z, et al. Scientific Impact Award: axillary reverse mapping (ARM) to identify and protect lymphatics draining the arm during axillary lymphadenectomy. Am J Surg. 2009; 198: 482-487.
218. Boneti C, Korourian S, Bland K, et al. Axillary reverse mapping: mapping and preserving arm lymphatics may be important in preventing lymphedema during sentinel lymph node biopsy. J Am Coll Surg, 2008; 206: 1038-1042; discussion 1042-1044.
219. Bedrosian I, Babiera GV, Mittendorf EA, et al. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients. Cancer. 2010; 116: 2543-2548.
220. Noguchi M, Yokoi M, Nakano Y,. Axillary reverse mapping with indocyanine fluorescence imaging in patients with breast cancer. J Surg Oncol. 2010; 101: 217-221.
221. Thompson M, Korourian S, Henry-Tillman R, et al. Axillary reverse mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol. 2007; 14: 1890-1895.
222. Nos C, Kaufmann G, Clough KB, et al. Combined axillary reverse mapping (ARM) technique for breast cancer patients requiring axillary dissection. Ann Surg Oncol. 2008; 15: 2550-2555.
223. Boccardo F, Casabona F, De Cian F, et al. Lymphedema microsurgical preventive healing approach: a new technique for primary prevention of arm lymphedema after mastectomy. Ann Surg Oncol. 2009; 16: 703-708.
224. Boccardo F, Casabona F, DeCian F, et al. Lymphatic microsurgical preventing healing approach (LYMPHA) for primary surgical prevention of breast cancer-related lymphedema: over 4 years follow-up. Microsurgery. 2014; 34: 421-424.
225. Morotti M, Menada MV, Boccardo F, et al. Lymphedema microsurgical preventive healing approach for primary prevention of lower limb lymphedema after inguinofemoral lymphadenectomy for vulvar cancer. Int J Gynecol Cancer. 2013; 23: 769-774.
226. Stout NL, Binkley JM, Schmitz KH, et al. A prospective surveillance model for rehabilitation for women with breast cancer. Cancer. 2012; 118: 2191-2200.
227. Torres Lacomba M, Yuste Sanchez MJ, Zapico Goni A, et al. Effectiveness of early physiotherapy to prevent lymphoedema after surgery for breast cancer: randomised, single blinded, clinical trial. BMJ. 2010; 340: b5396.
228. Boccardo FM, Ansaldi F, Bellini C, et al. Prospective evaluation of a prevention protocol for lymphedema following surgery for breast cancer. Lymphology. 2009; 42: 1-9.
229. Hayes SC, Rye S, Battistutta D, DiSipio T, Newman B,. Upper-body morbidity following breast cancer treatment is common, may persist longer-term and adversely influences quality of life. Health Qual Life Outcomes. 2010; 8: 92.
230. Shih YC, Xu Y, Cormier JN, et al. Incidence, treatment costs, and complications of lymphedema after breast cancer among women of working age: a 2-year follow-up study. J Clin Oncol. 2009; 27: 2007-2014.
231. Ahmed RL, Prizment A, Lazovich D, Schmitz KH, Folsom AR,. Lymphedema and quality of life in breast cancer survivors: the Iowa Women's Health Study. J Clin Oncol. 2008; 26: 5689-5696.
232. Springer BA, Levy E, McGarvey C, et al. Pre-operative assessment enables early diagnosis and recovery of shoulder function in patients with breast cancer. Breast Cancer Res Treat. 2010; 120: 135-147.
233. Levy EW, Pfalzer LA, Danoff J, et al. Predictors of functional shoulder recovery at 1 and 12 months after breast cancer surgery. Breast Cancer Res Treat. 2012; 134: 315-324.
234. Gerber LH, Stout N, McGarvey C, et al. Factors predicting clinically significant fatigue in women following treatment for primary breast cancer. Support Care Cancer. 2011; 19: 1581-1591.
235. Gerber LH, Stout NL, Schmitz KH, Stricker CT,. Integrating a prospective surveillance model for rehabilitation into breast cancer survivorship care. Cancer. 2012; 118: 2201-2206.
236. Blome C, Augustin M, Heyer K, et al. Evaluation of patient-relevant outcomes of lymphedema and lipedema treatment: development and validation of a new benefit tool. Eur J Vasc Endovasc Surg. 2014; 47: 100-107.
237. Cheville AL, Almoza M, Courmier JN, Basford JR,. A prospective cohort study defining utilities using time trade-offs and the Euroqol-5D to assess the impact of cancer-related lymphedema. Cancer. 2010; 116: 3722-3731.
238. Greenslade MV, House CJ,. Living with lymphedema: a qualitative study of women's perspectives on prevention and management following breast cancer-related treatment [article in English, French]. Can Oncol Nurs J. 2006; 16: 165-179.
239. Stout NL, Weiss R, Feldman JL, et al. A systematic review of care delivery models and economic analyses in lymphedema: health policy impact (2004-2011). Lymphology. 2013; 46: 27-41.
240. Stout NL, Pfalzer LA, Springer B, et al. Breast cancer-related lymphedema: comparing direct costs of a prospective surveillance model and a traditional model of care. Phys Ther. 2012; 92: 152-163.